| Literature DB >> 31937259 |
J Schuster, C Hoyer, A Ebert1, A Alonso2.
Abstract
BACKGROUND: Pain is a common and burdensome complication in patients with acute stroke. We assessed the impact of impaired communication in stroke patients on pain assessment and treatment.Entities:
Keywords: Analgesia; Consciousness disorder; Inability to communicate; Pain; Stroke
Mesh:
Substances:
Year: 2020 PMID: 31937259 PMCID: PMC6961294 DOI: 10.1186/s12883-020-1606-x
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Baseline characteristics
| AC | P-NAC | S-NAC | C-NAC | ||
|---|---|---|---|---|---|
| 746 (82.1) | 25 (2.8) | 90 (9.9) | 48 (5.3) | ||
| Demographics | |||||
| age, years, mean (SD) | 70.46 (15.55) | 79.6 (10.94) | 77.4 (12.56) | 78.27(13.59) | < 0.001abc |
| sex, male, | 427 (57.2) | 14 (56.0) | 50 (55.6) | 16 (33.3) | 0.015cf |
| living circumstances prior to index stroke | < 0.001abcde | ||||
| independent at home, | 669 (90.0) | 5 (20.0) | 53 (60.2) | 29 (60.4) | |
| family care, | 51 (6.9) | 9 (36.0) | 19 (21.6) | 9 (18.8) | |
| institutional care, | 23 (3.1) | 11 (44.0) | 16 (18.2) | 10 (20.8) | |
| premorbid mRS score >/= 3, | 92 (12.4) | 20 (80.0) | 26 (29.5) | 18 (38.3) | < 0.001abcde |
| Vascular risk factors | |||||
| atrial fibrillation | 168 (22.5) | 16 (64.0) | 50 (55.6) | 24 (50.0) | < 0.001abc |
| hypertension, | 612 (82.0) | 21 (84.0) | 83 (92.2) | 44 (91.7) | 0.03b |
| diabetes mellitus, | 205 (27.5) | 11 (44.0) | 26 (28.9) | 11 (22.9) | n.s. |
| dyslipidemia, | 285 (38.2) | 9 (36.0) | 29 (32.2) | 15 (31.3) | n.s. |
| coronary heart disease, | 166 (22.3) | 9 (36.0) | 34 (37.8) | 11 (22.9) | 0.006b |
| prior myocardial infarction, | 87 (11.7) | 1 (4.0) | 17 (18.9) | 7 (14.6) | n.s. |
| prior stroke, | 175 (23.5) | 11 (44.0) | 27 (30.0) | 18 (37.5) | 0.013ac |
| current or past smoker, | 197 (26.4) | 4 (16.0) | 10 (11.1) | 3 (6.3) | < 0.001bc |
| Comorbidities | |||||
| Dementia, | 58 (7.8) | 21 (84.0) | 20 (22.2) | 7 (14.6) | < 0.001abde |
| Depression, | 63 (8.4) | 6 (24.0) | 9 (10.0) | 6 (12.5) | n.s. |
| Cancer, | 33 (4.4) | 1 (4.0) | 9 (10.0) | 0 (0.0) | 0.049bf |
| Index stroke | |||||
| Ischemia, | 621 (83.2) | 23 (92.0) | 77 (85.6) | 38 (79.2) | |
| Intracerebral hemorrhage, | 50 (6.7) | 1 (4.0) | 13 (14.4) | 10 (20.8) | |
| TIA, | 75 (10.1) | 1 (4.0) | 0 (0.0) | 0 (0.0) | |
| NIHSS at admission, median (IQR) | 3 (5) | 10 (12) | 17.5 (12) | 23 (8) | < 0.001abcef |
| severe aphasia, | 67 (9.0) | 10 (40.0) | 67 (74.4) | 28 (59.6) | < 0.001abcd |
| severe dysarthria, | 51 (6.8) | 9 (36.0) | 39 (43.3) | 24 (50.0) | < 0.001abc |
| GCS < 12 at admission, | 2 (0.3) | 1 (4.0) | 7 (7.8) | 18 (37.5) | < 0.001bcef |
| Length of hospital stay, days, mean (SD) | 11.2 (6.6) | 10.6 (6.9) | 13.3 (8.3) | 9.2 (7.7) | < 0.001bcf |
| In-hospital death, | 1 (0.1) | 5 (20.0) | 10 (11.1) | 37 (77.1) | < 0.001abcdef |
a, significant group difference AC vs P-NAC
b, significant group difference AC vs S-NAC
c, significant group difference AC vs C-NAC
d, significant group difference P-NAC vs S-NAC
e, significant group difference P-NAC vs C-NAC
f, significant group difference S-NAC vs C-NAC
Assessment of pain and use of analgesics
| AC | P-NAC | S-NAC | p-value | |
|---|---|---|---|---|
| Number of patients, | 746 (86.6) | 25 (2.9) | 90 (10.5) | |
| Assessment of pain | ||||
| Any, | 741 (99.5) | 25 (100.0) | 89 (98.9) | n.s. |
| Any, | 161 (21.6) | 13 (52.0) | 57 (63.3) | < 0.001ab |
| NRS, | 738 (99.1) | 25 (100.0) | 85 (94.4) | < 0.012b |
| NRS, frequency, | 2.44 (1.10) | 2.02 (1.33) | 1.68 (0.96) | n.s. |
| Pain prevalence | ||||
| Total, | 353 (47.3) | 11 (44.0) | 38 (42.2) | n.s. |
| Headache, | 188 (25.2) | 4 (16.0) | 10 (11.1) | 0.008b |
| Musculoskeletal pain, | 82 (11.0) | 1 (4.0) | 13 (14.4) | n.s. |
| Chronic pain syndrome, | 36 (4.8) | 0 (0.0) | 1 (1.1) | n.s. |
| Not specified, | 199 (26.7) | 7 (28.0) | 26 (28.9) | n.s. |
| Use of analgesics | ||||
| Any analgesic, | 363 (48.7) | 19 (76.0) | 70 (77.8) | < 0.001ab |
| Opioid, | 54 (7.2) | 5 (20.0) | 16 (17.8) | 0.001ab |
| Non-Opioid, | 278 (37.3) | 11 (44.0) | 56 (62.2) | < 0.001b |
| Co-analgesic, | 165 (22.1) | 13 (52.0) | 21 (23.3) | 0.002ac |
| Indication | ||||
| Acute or chronic pain, | 245 (32.8) | 3 (12.0) | 22 (24.4) | 0.029a |
| Prophylactic treatment, | 3 (0.4) | 5 (20.0) | 13 (14.4) | < 0.001ab |
| Not documented, | 64 (8.6) | 5 (20.0) | 18 (20.0) | 0.001b |
| Other, | 148 (19.8) | 15 (60.0) | 43 (47.8) | 0.000ab |
| Documented response to treatment, | 120/245 (49.0) | 1/3 (33.3) | 2/22 (9.1) | < 0.001b |
a, significant group difference AC vs P-NAC
b, significant group difference AC vs S-NAC
c, significant group difference P-NAC vs S-NAC